Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments Nov 8, 2024
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock Oct 30, 2024
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock Oct 28, 2024
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate Oct 24, 2024
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 Oct 22, 2024
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers Oct 15, 2024
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers Oct 7, 2024
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr Sep 12, 2024
